These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26825099)

  • 1. Augmented trial designs for evaluation of principal surrogates.
    Gabriel EE; Follmann D
    Biostatistics; 2016 Jul; 17(3):453-67. PubMed ID: 26825099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials.
    Liu W; Zhang B; Zhang H; Zhang Z
    Stat Methods Med Res; 2017 Apr; 26(2):984-996. PubMed ID: 25549966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis of crossover trials for absorbing binary endpoints.
    Nason M; Follmann D
    Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and comparison of predictive individual-level general surrogates.
    Gabriel EE; Sachs MC; Halloran ME
    Biostatistics; 2018 Jul; 19(3):307-324. PubMed ID: 28968890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints.
    Gabriel EE; Sachs MC; Gilbert PB
    Stat Med; 2015 Feb; 34(3):381-95. PubMed ID: 25352131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive cluster level surrogacy in the presence of interference.
    Gabriel EE; Follmann DA
    Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.
    Yan Z; Hosmane B; Locke C
    J Biopharm Stat; 2013; 23(4):804-17. PubMed ID: 23786490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different methods to analyze stepped wedge trial designs revealed different aspects of intervention effects.
    Twisk JW; Hoogendijk EO; Zwijsen SA; de Boer MR
    J Clin Epidemiol; 2016 Apr; 72():75-83. PubMed ID: 26586107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.
    Qin L; Gilbert PB; Follmann D; Li D
    Ann Appl Stat; 2008 Mar; 2(1):386-407. PubMed ID: 19079758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal and efficient crossover designs under different assumptions about the carryover effects.
    Hedayat AS; Stufken J
    J Biopharm Stat; 2003 Aug; 13(3):519-28. PubMed ID: 12921398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inference on treatment effect modification by biomarker response in a three-phase sampling design.
    Juraska M; Huang Y; Gilbert PB
    Biostatistics; 2020 Jul; 21(3):545-560. PubMed ID: 30590450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
    Cellamare M; Ventz S; Baudin E; Mitnick CD; Trippa L
    Clin Trials; 2017 Feb; 14(1):17-28. PubMed ID: 27559021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing biomarkers as trial level general surrogates.
    Gabriel EE; Daniels MJ; Halloran ME
    Biometrics; 2016 Dec; 72(4):1046-1054. PubMed ID: 27038302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and estimation for evaluating principal surrogate markers in vaccine trials.
    Huang Y; Gilbert PB; Wolfson J
    Biometrics; 2013 Jun; 69(2):301-9. PubMed ID: 23409839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative randomized trials.
    Lee JT
    J Am Coll Surg; 2013 Jul; 217(1):171-2. PubMed ID: 23791291
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials: relevance of correlation between treatment responses.
    Cleophas TJ
    Eur J Clin Pharmacol; 1996; 50(1-2):1-6. PubMed ID: 8739804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; De Rycke Y; Guillo S; Foulon S; Tubach F
    BMC Med Res Methodol; 2017 Feb; 17(1):25. PubMed ID: 28178924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints.
    Wolfson J; Henn L
    Emerg Themes Epidemiol; 2014; 11():14. PubMed ID: 25342953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some statistical issues in the design of HIV-1 vaccine and treatment trials.
    Gilbert PB
    Stat Methods Med Res; 2000 Jun; 9(3):207-29. PubMed ID: 11084705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity analysis of causal inference in a clinical trial subject to crossover.
    Xie H; Heitjan DF
    Clin Trials; 2004 Feb; 1(1):21-30. PubMed ID: 16281459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.